"versionIdentifier","rationale","instanceType","uuid:ID","id"
"2","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","StudyVersion","1cba5d8d-bd91-4773-a32c-6c9c5ab2a17c","StudyVersion_1"
